Seeking Alpha

Grant Zeng, CFA's  Instablog

Grant Zeng, CFA
Send Message
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst... More
My company:
Zacks Investment Research, Inc.
  • Enrollment Of Phase II Clinical Trial Of ICT-107 Is Ahead Of Schedule  0 comments
    Jan 24, 2012 10:25 AM

    On Jan 23, ImmunoCellular Therapeutics, Ltd. (IMUC) provided an update on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107 for the treatment of glioblastoma multiforme (GBM).

    The Company has initiated the trial in 23 centers and has received Institutional Review Board (IRB) approval from a total of 24 trial sites. The trial is expected to enroll approximately 160-200 patients to treat 102 patients with HLA-A1/A2 immunological subtypes. There are 115 patients enrolled in the study to date, ahead of the Company's schedule. Enrollment for the trial is expected to be completed by the second quarter of 2012 and an interim analysis is expected when 50% of events (32 deaths) have been observed.

    As a reminder, the Company initiated the Phase II trial of ICT-107 for the treatment of newly diagnosed GBM following resection and chemoradiation in January 2011. The Phase II trial is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. The study is enrolling patients at medical institutions in collaboration with leading experts and opinion leaders in neuro-oncology at those sites.

    Patients will receive at least four intradermal injections of the ICT-107 vaccine and additional doses of vaccine during a maintenance phase until disease progression. The primary objective is to compare overall survival (OS) and progression free survival (NYSE:PFS) in patients when treated with ICT-107 versus control.

    The Phase I clinical study of ICT-107 in GBM, 16 newly diagnosed patients who received the vaccine in addition to standard of care of surgery, radiation and chemotherapy demonstrated two year overall survival of 80 percent and a three year survival of 55 percent. These figures compare favorably to the 26 percent two-year and 16 percent three-year survival based on the historical standard of care treatment alone. The median overall survival was 38.4 months compared to 14.6 months for the historical standard of care. The study's median progression free survival (PFS) of 16.9 months compared favorably to the historic median PFS of 6.9 months. Six out of the 16 (37.6%) newly diagnosed patients who received ICT-107 continue to show no tumor recurrence at the last analysis, with 3 of these patients (18.8%) remaining disease-free for more than 4 years while the other 3 patients had gone more than 3 years disease-free. There have been no serious adverse treatment related symptoms observed in any of the patients.

    Phase I trial result summary

       

    ICT107 + SOC*

     

    SOC (Stupp, NEJM, 2005)

       

    (n=16)

     

    (n=287)

          
     

    Median Age

     

    52

     

    56

          

    PFS (%)

    At 6 months

     

    100

     

    53.9

     

    At 12 months

     

    62.5

     

    26.9

     

    At 18 months

     

    43.8

     

    18.4

     

    At 24 months

     

    43.8

     

    10.7

     

    At 36 months

     

    38.0

     

    6.0

     

    Median (months)

    16.9

     

    6.9

          

    OS (%)

    At 6 months

     

    100

     

    86.3

     

    At 12 months

     

    100

     

    61.1

     

    At 18 months

     

    93.8

     

    39.4

     

    At 24 months

     

    80.2

     

    26.5

     

    At 36 months

     

    55.0

     

    16.0

     

    Median (months)

    NR = 38.4

     

    14.6

          

    *SOC= Standard of Care (XRT +TMZ); NR=Not reached

    Based on the positive Phase I clinical trial results, the probability of positive Phase II results is high. Unlike the Phase I which showed a 24-month increase in OS, a six-month increase in OS would be considered successful and clinically relevant for this disease as the current standard of care increases OS by 2.5 months. Upon the successful conclusion of the Phase II study, IMUC anticipates a lucrative partnering contract with a major pharmaceutical or biotech company. The partnership may include a large sum of upfront payment, milestone fees and high royalties.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Themes: Biotech
Back To Grant Zeng, CFA's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.